ProBioGen licenses GlymaxX tech to Sanofi
Berlin-based ProBioGen AG has signed a commercial multi-product license agreement with Sanofi. Under the agreement, Sanofi will integrate ProBioGen’s proprietary GlymaxX technology into their product development strategy for an undisclosed number of antibody candidates across several business units.
GlymaxX enables a boost of antibody-dependent cell-mediated cytotoxicity (ADCC), consequently leading to an elevated NK cell mediated killing activity of its target cells. The GlymaxX technology adds value to the products by significantly improving their potency and potentially reducing the overall clinical doses for patients.
The GlymaxX technology for production of afucosylated proteins is widely applied in the pharma industry and hence used in various numbers of mAb candidates. It is universally applicable, simple and very potent.
The unique advantage of the GlymaxX technology allows a single GlymaxX modified cell line to produce both, completely fucosylated and/or afucosylated antibodies and those with intermediate defined fuscosylation levels.
The technology can be easily integrated in newly developed or already existing cell lines of different host cell origins, which demonstrates its great flexibility.
ProBioGen is a premier CDMO for developing and manufacturing complex therapeutic glycoproteins. The GlymaxX technology, developed by ProBioGen, prevents the addition of the sugar “fucose” to the N-linked antibody carbohydrate part by antibody producing cells. The absence of fucose enhances ADCC (antibody-dependent cell-mediated cytotoxicity) activity for antibodies directed against cancer and infectious diseases. The GlymaxX technology is based on the stable introduction of a gene for an enzyme which deflects the cellular pathway of fucose biosynthesis. ProBioGen offers this technology royalty-free to third parties.
- For more information, see: http://www.glymaxx.com/
